Shah Nikita 4
4 · Amneal Pharmaceuticals, Inc. · Filed Nov 14, 2025
Insider Transaction Report
Form 4
Shah Nikita
Executive Vice President
Transactions
- Exercise/Conversion
Class A Common Stock
2025-11-12$2.75/sh+95,525$262,694→ 278,259 total - Sale
Class A Common Stock
2025-11-12$11.92/sh−131,856$1,571,724→ 146,403 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-12−36,331→ 0 totalExercise: $2.75Exp: 2028-05-07→ Class A Common Stock (36,331 underlying) - Exercise/Conversion
Class A Common Stock
2025-11-12$2.75/sh+36,331$99,910→ 182,734 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-12−95,525→ 0 totalExercise: $2.75Exp: 2029-03-01→ Class A Common Stock (95,525 underlying)
Footnotes (2)
- [F1]The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.85 to $12.02 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]This option is fully vested.